DermTech, Inc. (NASDAQ:DMTK – Get Rating) – Equities research analysts at Oppenheimer boosted their Q3 2022 earnings per share estimates for shares of DermTech in a report released on Tuesday, August 16th. Oppenheimer analyst F. Brisebois now forecasts that the company will earn ($0.98) per share for the quarter, up from their previous estimate of ($1.06). Oppenheimer has a "Outperform" rating and a $23.00 price objective on the stock. The consensus estimate for DermTech's current full-year earnings is ($4.02) per share. Oppenheimer also issued estimates for DermTech's Q4 2022 earnings at ($0.97) EPS, FY2022 earnings at ($3.95) EPS, Q1 2023 earnings at ($1.02) EPS, Q2 2023 earnings at ($0.85) EPS, Q3 2023 earnings at ($0.85) EPS, Q4 2023 earnings at ($0.84) EPS and FY2023 earnings at ($3.53) EPS.

A number of other brokerages have also weighed in on DMTK. Craig Hallum decreased their price objective on DermTech from $37.00 to $18.00 in a report on Tuesday, August 9th. BTIG Research cut their target price on DermTech from $19.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, August 15th. Lake Street Capital cut their target price on DermTech from $34.00 to $14.00 in a research note on Tuesday, August 9th. Finally, Cowen cut their target price on DermTech from $33.00 to $20.00 in a research note on Wednesday, May 4th.

DermTech Price Performance

Institutional Trading of DermTech

A number of hedge funds and other institutional investors have recently modified their holdings of DMTK. Financial Management Professionals Inc. purchased a new position in DermTech during the 2nd quarter valued at about $26,000. Wolverine Asset Management LLC purchased a new position in DermTech during the 4th quarter valued at about $43,000. Wedbush Securities Inc. purchased a new position in DermTech during the 2nd quarter valued at about $58,000. Amalgamated Bank purchased a new position in DermTech during the 1st quarter valued at about $58,000. Finally, Valeo Financial Advisors LLC purchased a new position in shares of DermTech in the 2nd quarter valued at about $60,000. 75.12% of the stock is owned by institutional investors and hedge funds.

About DermTech

(Get Rating)

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

Further Reading

• Get a free copy of the StockNews.com research report on DermTech (DMTK)
• 2 EV Suppliers Powering To Gains After Raising Views
• Applied Materials Results Show A Slowing Semiconductor Market
• MarketBeat: Week in Review 8/15 – 8/19
• Near-Term Headwinds Present An Opportunity In Ross Stores
• Apple's Stock Could Be On The Verge Of Another 30% Rally

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.